Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Inhibition of UDP-glucuronosyltransferase by aglycons of natural glucuronides in kampo medicines using SN-38 as a substrate.

Literature DB >> 7493919

Inhibition of UDP-glucuronosyltransferase by aglycons of natural glucuronides in kampo medicines using SN-38 as a substrate.

T Yokoi¹, M Narita, E Nagai, H Hagiwara, M Aburada, T Kamataki.

Abstract

7-Ethyl-10-[4-(piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11), a potent anticancer agent for lung and gynecological cancers, is metabolized in vivo to the active compound, 7-ethyl-10-hydroxycamptothecin (SN-38), which is subsequently conjugated to SN-38-glucuronide by UDP-glucuronosyltransferase (UDP-GT). Three purified aglycons of natural glucuronides, baicalein, luteolin and glycyrrhetic acid, inhibited UDP-GT activity towards SN-38 as a substrate. The inhibitory potencies of these aglycons toward UDP-GT were similar to that of 1-naphthol. Based on these results, together with our previous finding that the corresponding glucuronides used in the present study strongly inhibited beta-glucuronidase in gut flora, we propose that materials in Kampo (Japanese herbal) medicines containing these aglycons of natural glucuronides could be used in vivo to decrease the enterohepatic circulation of SN-38 and other drugs.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 1995 PMID： 7493919 PMCID： PMC5920600 DOI： 10.1111/j.1349-7006.1995.tb03011.x

Source DB: PubMed Journal: Jpn J Cancer Res ISSN： 0910-5050

camptothecin 7.ethyl‐10‐[4‐(piperidino)‐l‐piperidino]carbonyloxycamptotheciu dimethyl sulfoxide; SN‐38, 7‐ethyl‐lo‐hydroxycamptothecin 7.ethyl‐10.hydroxycamptothecin glucuro‐nide uridine 5′.diphosphoglucuronic acid UDP‐glucuronosyltransferase

17 in total

1. An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma.

Authors: R Ohno; K Okada; T Masaoka; A Kuramoto; T Arima; Y Yoshida; H Ariyoshi; M Ichimaru; Y Sakai; M Oguro
Journal: J Clin Oncol Date: 1990-11 Impact factor: 44.544

2. Effects of lyophilization and storage of rat liver microsomes on activity of aniline hydroxylase, contents of cytochrome b5 and cytochrome p-450 and aniline-induced p-450 difference spectrum.

Authors: T Kamataki; H Kitagawa
Journal: Jpn J Pharmacol Date: 1974-04

3. [Phase I clinical study of CPT-11. Research group of CPT-11].

Authors: T Taguchi; A Wakui; K Hasegawa; H Niitani; H Furue; K Ohta; T Hattori
Journal: Gan To Kagaku Ryoho Date: 1990-01

4. UDP-glucuronosyltransferase activities. Guidelines for consistent interim terminology and assay conditions.

Authors: K W Bock; B Burchell; G J Dutton; O Hänninen; G J Mulder; I S Owens; G Siest; T R Tephly
Journal: Biochem Pharmacol Date: 1983-03-15 Impact factor: 5.858

5. Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I.

Authors: T Andoh; K Ishii; Y Suzuki; Y Ikegami; Y Kusunoki; Y Takemoto; K Okada
Journal: Proc Natl Acad Sci U S A Date: 1987-08 Impact factor: 11.205

6. Inhibition of beta-glucuronidase by natural glucuronides of kampo medicines using glucuronide of SN-38 (7-ethyl-10-hydroxycamptothecin) as a substrate.

Authors: M Narita; E Nagai; H Hagiwara; M Aburada; T Yokoi; T Kamataki
Journal: Xenobiotica Date: 1993-01 Impact factor: 1.908

7. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors.

Authors: T Kunimoto; K Nitta; T Tanaka; N Uehara; H Baba; M Takeuchi; T Yokokura; S Sawada; T Miyasaka; M Mutai
Journal: Cancer Res Date: 1987-11-15 Impact factor: 12.701

8. Characterization of microsomal bilirubin and p-nitrophenol uridine diphosphate glucuronosyltransferase activities in human liver: a comparison with rat liver.

Authors: J L Mahu; A M Preaux; P Mavier; P Berthelot
Journal: Enzyme Date: 1981

9. Nonlinear pharmacokinetics of CPT-11 in rats.

Authors: N Kaneda; T Yokokura
Journal: Cancer Res Date: 1990-03-15 Impact factor: 12.701

10. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse.

Authors: N Kaneda; H Nagata; T Furuta; T Yokokura
Journal: Cancer Res Date: 1990-03-15 Impact factor: 12.701

4 in total

1. Effects of the flavonoid baicalin and its metabolite baicalein on androgen receptor expression, cell cycle progression and apoptosis of prostate cancer cell lines.

Authors: S Chen; Q Ruan; E Bedner; A Deptala; X Wang; T C Hsieh; F Traganos; Z Darzynkiewicz
Journal: Cell Prolif Date: 2001-10 Impact factor: 6.831